Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Stock Quotes and News

Anthera Pharmaceuticals, Inc. (ANTH) 0.62 -0.007

Price Open:	0.599	Day's Range:	0.00000 - 1.17000
Price Close:	0.6069	52wk Range:	0.00000 - 8.42
Price Day Change:	-0.007	Volume:	626,593
Price % Change:	-1.15	Market Cap:	91.6M
Bid:	0.57000	PE Ratio:	0
Ask:	0.61900	EPS Diluted:	-0.586

Trade ANTH NOW!

The Latest On ANTH

Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study 5/7/13 4:32pm

UPDATE: Jefferies Initiates Anthera Pharmaceuticals at Buy on Blisibimod Outlook 3/5/13 9:26am

Benzinga's Microcap Movers for Monday September 17, 2012 9/17/12 10:29pm

Anthera Announces the Advancement of Blisibimod into Phase 3 Development 9/17/12 8:02am

Benzinga's Microcap Movers for Friday August 24, 2012 8/26/12 9:27am

Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock; 33M Shares at $1.00/Share 7/19/12 9:16am

Benzinga's Microcap Movers for Wednesday July 18, 2012 7/18/12 10:00pm

Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock; No Amount Given 7/18/12 4:23pm

Benzinga's Microcap Movers for Tuesday July 17, 2012 7/17/12 4:57pm

Benzinga's Microcap Movers for Monday July 16, 2012 7/16/12 4:38pm

Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population 7/16/12 8:45am

UPDATE: Citigroup Downgrades Anthera Pharmaceuticals to Sell on Modest Efficacy to Drug Phase 2 6/29/12 8:08am

Press Releases

Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results 5/13/13 Newswire

Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study 5/7/13 Newswire

Anthera Announces First Quarter 2013 Financial Report and Conference Call 5/3/13 Newswire

Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility 4/5/13 Newswire

Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod 3/27/13 Newswire

Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results 3/26/13 Newswire

Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus 3/22/13 Newswire

Faruqi & Faruqi, LLP is Investigating Anthera Pharmaceuticals Incorporated on Behalf of its Shareholders - ANTH 2/13/13 Newswire

Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference 2/7/13 Newswire

Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil 2/5/13 Newswire

Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock 1/30/13 Newswire

Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock 1/25/13 Newswire

Get the latest ANTH stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Anthera Pharmaceuticals, Inc. stock price.

Partner Headlines

ANTH's Blisibimod Enters Phase III - Analyst Blog 4/1/13

Two Down (Well, Up) and One To Go: RNN, ANTH, and ARNA in Focus 1/8/13

Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) 11/8/12

How Close Are These Biotechs to Breakouts? DARA, ZGNX, ANTH in Focus. 9/17/12

Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) 8/9/12

Profit from RiT Technologies Ups and Downs (RITT, DGIT, ANTH) 7/17/12

For Anthera Pharmaceuticals (ANTH), the Glass is Half Full Rather Than Half Empty 7/17/12

Will the GlaxoSmithKline plc (GSK) Purchase of Human Genome Sciences (HGSI) Set Off a Wave of M&A? LJPC, ROSG, ANTH, GENE 7/16/12

Anthera Pharmaceuticals Inc. (ANTH) CEO Paul F Truex buys 20,000 Shares 7/2/12

ProShares Trust Ultra VIX Short Term Futures ETF, Nokia Corporation Among Stocks setting 52-Week Lows Friday 6/29/12

Upgrades & Downgrades 6/29/12